Earnings summaries and quarterly performance for LivaNova.
Executive leadership at LivaNova.
Board of directors at LivaNova.
Brooke Story
Detailed
Director
Donald Zurbay
Detailed
Director
Dr. Sharon O’Kane
Detailed
Director
Francesco Bianchi
Detailed
Director
J. Christopher Barry
Detailed
Director
Peter Wilver
Detailed
Director
Stacy Enxing Seng
Detailed
Director
Susan Podlogar
Detailed
Director
Todd Schermerhorn
Detailed
Director
William Kozy
Detailed
Chair of the Board
Research analysts who have asked questions during LivaNova earnings calls.
Adam Maeder
Piper Sandler Companies
4 questions for LIVN
Also covers: ABT, AXNX, EW +13 more
David Rescott
Baird
4 questions for LIVN
Also covers: HAE, INSP, IRTC +7 more
David Roman
Goldman Sachs Group Inc.
4 questions for LIVN
Also covers: ABT, BAX, BDX +18 more
Frederick Wise
Stifel
3 questions for LIVN
Also covers: AORT, ATRC, AVNS +13 more
Michael Polark
Wolfe Research
3 questions for LIVN
Also covers: BSX, DXCM, EMBC +11 more
Matthew Miksic
Barclays PLC
2 questions for LIVN
Also covers: ABT, ATEC, BAX +15 more
Michael Matson
Needham & Company
2 questions for LIVN
Also covers: AORT, ATRC, CNMD +22 more
Anthony Petrone
Mizuho Group
1 question for LIVN
Also covers: ADMA, ALC, BSX +22 more
Matthew Taylor
Jefferies
1 question for LIVN
Also covers: ALUR, BDX, CQP +18 more
Matt Miksic
Barclays Investment Bank
1 question for LIVN
Also covers: ABT, ATEC, BAX +14 more
Matt Taylor
Jefferies & Company Inc.
1 question for LIVN
Also covers: BAX, BIO, DXCM +10 more
Michael Sarcone
Jefferies
1 question for LIVN
Also covers: ALC, AXGN, CTSO +11 more
Mike Polark
Wolfe Research, LLC
1 question for LIVN
Also covers: BBNX, BSX, DXCM +6 more
Rick Wise
Stifel Financial Corp
1 question for LIVN
Also covers: BDX, BSX, GEHC +8 more
Recent press releases and 8-K filings for LIVN.
LivaNova Discusses 2025 Outlook, Long-Range Plan, and Key Product Launches
LIVN
Guidance Update
Product Launch
New Projects/Investments
- LivaNova expects to achieve 9.5%-10.5% full-year growth for 2025 and projects mid- to high-single-digit top-line and EPS growth for its 2025-2028 Long-Range Plan, targeting a 20% operating margin.
- The company anticipates a significant 40%-50% increase in facility reimbursement for VNS Therapy (de novo implants and replacements) effective January 1, 2026, which is expected to remove economic barriers for hospitals and drive volume.
- Key product developments include the launch of the Essence Air Manager and a new heater/cooler in 2026, a next-generation IPG for epilepsy in 2027, and a next-generation oxygenator in 2028.
- For Obstructive Sleep Apnea (OSA), LivaNova targets $200 million-$400 million in revenue by 2030, with a next-generation device launching in late 2027 following heavy R&D investment in early 2026 and the recent hiring of a global head of commercialization.
Dec 2, 2025, 6:30 PM
LivaNova Discusses 2025 Outlook, 2026 Growth Drivers, and Key Product Developments
LIVN
Guidance Update
Product Launch
New Projects/Investments
- LivaNova projects 9.5%-10.5% full-year growth for 2025, with mid-to-high single-digit revenue and adjusted EPS growth targeted for 2025-2028, aiming for a 20% operating margin.
- Effective January 1, 2026, facility reimbursement for de novo VNS implants will increase by 40%-50%, eliminating the current $10,000-$15,000 average loss per procedure for hospitals and potentially unlocking significant volume.
- The company plans to launch new hardware for its Heart-Lung Machine (HLM) in 2026 and a next-generation oxygenator in 2028, targeting 45% oxygenator market share by 2030.
- LivaNova is heavily investing in R&D for its next-generation Obstructive Sleep Apnea (OSA) device, targeting $200 million-$400 million in OSA revenue by 2030, with a soft launch in H1 2027 and full launch in H2 2027.
Dec 2, 2025, 6:30 PM
LivaNova outlines strategic transformation and growth targets across key businesses
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova is executing a portfolio transformation to achieve durable, accelerated top and bottom-line growth by shifting towards larger, faster-growing, and more profitable markets.
- The company forecasts mid-single-digit growth for its epilepsy business through 2030, supported by core innovation, improved reimbursement (CMS upgrade for replacement devices to level five), and the upcoming launch of a cloud platform in 2026 for remote titration.
- LivaNova expects mid to high single-digit growth in its cardiopulmonary business over the next three to five years, driven by the SNs upgrade cycle and significant oxygenator market share gains, including 10 share points in the last two years and a target of an additional 800 basis points.
- A new strategic focus on the sleep apnea (OSA) market aims for $200 million to $400 million in revenue by 2030, leveraging a device with 15 years of battery life and a novel Polysync titration algorithm.
- The company forecasts mid to high single-digit revenue and EPS CAGR from 2025 to 2028, followed by 25% earnings growth in the subsequent years, while maintaining an annual AOI margin of 20%, reflecting a "generational investment cycle" in sleep apnea.
Nov 17, 2025, 7:40 PM
LivaNova outlines portfolio transformation, growth strategies, and financial targets
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova is pursuing a portfolio transformation to achieve durable, accelerated growth in faster-growing and more profitable markets.
- The company projects mid-single-digit growth for its Epilepsy business, with low single-digit growth for replacement devices and mid to high single-digit growth for new patients.
- For the Cardiopulmonary business, LivaNova forecasts mid to high single-digit growth over the next three to five years, aiming for an additional 800 basis points of market share gains in oxygenators after gaining 10 share points in the last two years.
- LivaNova is making a significant investment in the Sleep Apnea market, expecting it to contribute $200 million to $400 million in revenue by 2030, leveraging its neuromodulation capabilities.
- The company's five-year vision for EPS growth includes a mid to high single-digit CAGR from 2025 to 2028, followed by 25% earnings growth in subsequent years, while maintaining an annual AOI margin of 20%.
Nov 17, 2025, 7:40 PM
LivaNova Outlines Growth Strategy and Financial Targets
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova is undergoing a portfolio transformation to achieve durable, accelerated growth, targeting mid to high single-digit revenue and EPS CAGR over 2025-2028 while maintaining an annual AOI Margin of 20%. This strategy includes significant investments in new growth areas.
- The company forecasts mid-single-digit growth for its epilepsy business through 2030, driven by refocusing on core innovation, improved reimbursement (including a recent CMS upgrade to Level Five for replacement devices), and clinical evidence. A cloud platform for remote titration is planned for launch in 2026.
- LivaNova expects mid to high single-digit growth over the next three to five years in its cardiopulmonary business, supported by its market leadership, the SNs upgrade cycle, and a target of an additional 800 basis points of oxygenator market share gains.
- LivaNova is entering the sleep apnea (OSA) market, projecting $200 million to $400 million in revenue by 2030 from this segment. This move is seen as an opportunity to enter a larger, faster-growing, and more profitable market, leveraging existing neuromodulation capabilities and differentiated clinical data.
Nov 17, 2025, 7:40 PM
LivaNova Presents 2030 Financial Targets and Strategic Plan
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova PLC hosted its 2025 Investor Day, outlining a strategic roadmap and long-range financial plan with 2030 targets including a high-single-digit-plus revenue compound annual growth rate (CAGR), low double-digit to mid-teens earnings-per-share CAGR, adjusted annual operating margin above 20% over the next three years targeting high twenties by 2030, and adjusted free cash flow conversion above 80%.
- The company's strategy is built on maximizing its core Cardiopulmonary and Epilepsy businesses, scaling Obstructive Sleep Apnea (OSA), and preserving upside in Difficult-to-Treat Depression (DTD).
- The Obstructive Sleep Apnea (OSA) business is projected to generate $200 million to $400 million in revenue by 2030, achieve an adjusted operating income margin of greater than 25%, and is expected to be break-even by 2029 following planned commercialization in 2027.
- Difficult-to-Treat Depression (DTD) is considered a significant upside option, though it is not included in the long-range financial projections due to pending coverage reconsideration with the U.S. Centers for Medicare & Medicaid Services (CMS).
Nov 12, 2025, 8:26 PM
LivaNova Outlines Strategic Vision and Financial Targets at Investor Day
LIVN
Guidance Update
New Projects/Investments
Management Change
- LivaNova highlights its strong core Epilepsy and Cardiopulmonary businesses, which are market-leading and generate steady growth and strong cash. The Cardiopulmonary segment has achieved double-digit revenue and adjusted operating income growth for 11 consecutive quarters.
- The company is focused on transformative growth opportunities in Obstructive Sleep Apnea (OSA), a $1.0 billion market with double-digit CAGR, and has upside optionality with its Depression Treatment Device (DTD).
- LivaNova reported $1.3 billion in LTM Revenue and set 2025E-2030E financial targets including a high single-digit+ Revenue CAGR, maintaining >20% Adjusted Operating Margins through 2028 (reaching high 20s by 2030), and a low double-digit to mid-teens Adjusted EPS CAGR.
- The company has a refreshed leadership team with key appointments in 2024 and 2025, including Vladimir Makatsaria as CEO.
Nov 12, 2025, 2:00 PM
LivaNova Outlines Long-Range Financial Plan and Strategic Growth Initiatives
LIVN
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- LivaNova provided a long-range plan (2025-2030) forecasting high single-digit plus revenue CAGR and an exit adjusted operating income margin in the mid to high 20s. For 2025, the company expects organic revenue growth between 9.5-10.5%, adjusted operating income margin between 20-21%, adjusted diluted EPS between $3.80-$3.90, and adjusted free cash flow from operations between $160-$180 million.
- The company's strategy centers on driving mid-single-digit plus growth in its core Cardiopulmonary and Epilepsy businesses while investing in the new Obstructive Sleep Apnea (OSA) market.
- LivaNova projects OSA revenue of approximately $200-$400 million with an operating margin of 25% plus by 2030, and a break-even P&L by 2029, with the full commercial launch planned for the second half of 2027.
- Key investments include expanding manufacturing capacity for cardiopulmonary consumables, launching a new generation oxygenator by 2028, and advancing the Essence perfusion system. The company aims to maintain an annual adjusted operating margin above 20% during the initial OSA investment phase.
Nov 12, 2025, 2:00 PM
LivaNova Reports Strong Q3 2025 Results and Raises Full-Year Guidance
LIVN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- LivaNova reported Q3 2025 revenue of $358 million, representing 13% organic revenue growth and 11% constant currency growth versus the prior year.
- Adjusted diluted earnings per share for Q3 2025 increased to $1.11, compared to $0.90 in Q3 2024.
- The company raised its full-year 2025 organic revenue growth outlook to between 9.5% and 10.5% and adjusted diluted EPS guidance to a range of $3.80-$3.90.
- Segment performance in Q3 2025 included 16% revenue growth in Cardiopulmonary and 6% revenue growth in Epilepsy compared to the prior year.
- LivaNova's cash balance at September 30th, 2025, was $646 million, up from $429 million at year-end 2024, and total debt was reduced to $434 million from $628 million.
Nov 5, 2025, 1:00 PM
LIVN Reports Strong Q3 2025 Results and Raises Full-Year Guidance
LIVN
Earnings
Guidance Update
Product Launch
- LivaNova reported Q3 2025 net revenue of $358 million, representing 13% organic revenue growth and 11% constant-currency growth.
- For Q3 2025, adjusted diluted EPS was $1.11 and adjusted free cash flow was $62 million. The company also achieved an adjusted operating margin of 22.5%.
- The company raised its full-year 2025 guidance, with organic revenue growth now projected at 9.5% - 10.5%, adjusted diluted EPS at $3.80 - $3.90, and adjusted free cash flow at $160 million - $180 million.
- A key commercial milestone in Q3 2025 was the launch of the Essenz Perfusion System in China.
Nov 5, 2025, 1:00 PM
Quarterly earnings call transcripts for LivaNova.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more